What topical antibiotic eye drops are recommended for treating bacterial conjunctivitis, including dosing, alternatives for sulfonamide allergy, infants, and contact‑lens wearers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Topical Antibiotic Eye Drops for Bacterial Conjunctivitis

For uncomplicated bacterial conjunctivitis in adults and children, use azithromycin 1.5% eye drops (1 drop twice daily for 3 days) or a fluoroquinolone like besifloxacin 0.6% (1 drop three times daily for 7 days), though observation without antibiotics is also reasonable given the self-limited nature of most cases.

Standard Treatment Approach

First-Line Options for Typical Cases

The evidence supports several effective topical antibiotics, with choice depending on patient age, compliance concerns, and clinical context:

  • Azithromycin 1.5%: 1 drop twice daily for 3 days 1

    • Superior convenience and compliance compared to older regimens
    • Produces rapid resolution of purulent discharge (significantly more complete resolution by day 3 versus tobramycin) 1
    • Parents find this regimen substantially easier to use 1
  • Fluoroquinolones (besifloxacin, moxifloxacin): 1 drop three times daily for 7 days 2

    • Broad-spectrum coverage against common ocular pathogens including S. aureus, S. pneumoniae, and H. influenzae 2
    • Besifloxacin achieves clinical resolution in 58-73% of cases versus 33-43% with vehicle 2
  • Chloramphenicol 0.5%: 1 drop four times daily for 7-9 days 3

    • Simplified dosing (four times daily) is as effective as intensive hourly dosing with better compliance 3
    • Historically common, though less convenient than newer agents

Important Clinical Context: Consider Observation

Antibiotics provide only modest benefit over placebo - spontaneous resolution occurs in 55.5% of placebo-treated patients by days 4-9 versus 68.2% with antibiotics (RR 1.26) 4. Delayed antibiotic prescribing achieves similar symptom control as immediate prescribing 5. This supports a "watchful waiting" approach for mild cases, particularly given antibiotic resistance concerns.

Special Populations

Infants and Neonates

For neonatal conjunctivitis (ophthalmia neonatorum):

  • Fucidic acid 1.0%: 1 drop twice daily for 7 days 6

    • 89% cure rate, easier to use than chloramphenicol (90.7% vs 78% compliance) 6
  • Chloramphenicol 0.5%: 1 drop six times daily for 7 days 6

    • 87.9% cure rate, but more demanding dosing schedule 6

Critical caveat: Neonatal conjunctivitis requires immediate ophthalmology referral 5, as gonococcal and chlamydial infections require systemic antibiotics per CDC guidelines 7:

  • N. gonorrhoeae: Ceftriaxone 25-50 mg/kg IV/IM (single dose, max 250 mg)
  • Chlamydia: Erythromycin 50 mg/kg/day divided four times daily for 14 days or azithromycin suspension 20 mg/kg/day for 3 days

Contact Lens Wearers

Contact lens wearers require anti-pseudomonal coverage due to risk of Pseudomonas aeruginosa keratitis:

  • Use fluoroquinolones (besifloxacin, moxifloxacin, or ciprofloxacin) as first-line
  • Discontinue contact lens wear immediately
  • Consider ophthalmology referral if symptoms worsen or fail to improve within 24-48 hours

Sulfonamide Allergy

For patients allergic to sulfonamides, avoid trimethoprim-polymyxin combinations. Safe alternatives include:

  • Azithromycin 1.5% 1
  • Fluoroquinolones (besifloxacin, moxifloxacin) 2
  • Aminoglycosides (netilmicin, gentamicin) 8
  • Chloramphenicol 3

Netilmicin provides broader coverage than gentamicin (96.9% vs 75% bacterial sensitivity) with comparable safety 8.

Dosing Summary Table

Agent Dosing Duration Key Advantage
Azithromycin 1.5% 1 drop BID 3 days Best compliance, rapid resolution [1]
Besifloxacin 0.6% 1 drop TID (4-12h apart) 7 days Broad spectrum, minimal systemic absorption [2]
Chloramphenicol 0.5% 1 drop QID 7-9 days Cost-effective, proven efficacy [3]
Fucidic acid 1.0% (neonates) 1 drop BID 7 days Easier compliance in infants [6]

Critical Red Flags Requiring Ophthalmology Referral

Refer immediately if patient has 5:

  • Severe eye pain or photophobia
  • Decreased vision
  • Recent ocular surgery
  • Vesicular rash on eyelids/nose (suggests herpes)
  • Immunocompromised state
  • Neonatal age
  • Contact lens wearer with worsening symptoms

Safety Considerations

Topical antibiotics are generally well-tolerated. Most common adverse effects include 2:

  • Transient blurred vision (2.1%)
  • Eye irritation/pain (1.5%)
  • Non-specific conjunctivitis (2.6%)

No serious systemic side effects have been reported with topical ophthalmic antibiotics 4. Fluoroquinolones may cause fewer ocular side effects than non-fluoroquinolones (RR 0.70 vs 4.05) 4.

Practical Algorithm

  1. Confirm bacterial etiology: Mucopurulent discharge, eyelids matted shut (more common in children) 5
  2. Assess for red flags: If present → immediate ophthalmology referral
  3. Identify special populations: Neonate, contact lens wearer, or sulfa allergy
  4. Choose antibiotic based on compliance needs:
    • Best compliance needed → azithromycin 1.5% BID × 3 days
    • Contact lens wearer → fluoroquinolone TID × 7 days
    • Cost-conscious → chloramphenicol QID × 7-9 days
  5. Consider observation for mild cases in reliable patients who can return if worsening

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.